Company Filing History:
2 out of 72 
2 out of 3,685 
Years Active: 2022-2025
Title: Diana Yuhui Chen: Innovator in Antibody Research
Introduction
Diana Yuhui Chen is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of immunology, particularly in the development of antibodies that target specific proteins. With a total of 2 patents, her work is paving the way for advancements in therapeutic applications.
Latest Patents
Diana's latest patents focus on antibodies binding to immunoglobulin-like transcript 4 (ILT4), also known as LILRB2, LIR2, MIR10, and CD85d. These patents detail antibodies that specifically bind to human ILT4 while showing minimal binding to ILT2, ILT3, ILT5, and other members of the LILRA or LILRB families. This specificity is crucial for developing targeted therapies that minimize side effects and enhance treatment efficacy.
Career Highlights
Throughout her career, Diana has worked with notable companies in the biotechnology sector. She has been associated with Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company, where she has contributed her expertise in antibody development and immunology.
Collaborations
Diana has collaborated with several professionals in her field, including Xiao Min Schebye and Andrew Rankin. These collaborations have further enriched her research and innovation efforts.
Conclusion
Diana Yuhui Chen is a trailblazer in antibody research, with her innovative patents and collaborations driving advancements in immunotherapy. Her work continues to have a significant impact on the field, showcasing the importance of targeted treatments in modern medicine.